Healthcare ❯ Pharmaceuticals
Clinical Trials FDA Regulation Hemophilia Treatment Adverse Events Duchenne Muscular Dystrophy Cost of Treatment Regulatory Approval Patient Safety Rare Diseases
The hold follows a fatal capillary leak syndrome event prompting scrutiny of a newly introduced immune suppression agent
